MWNA
CRNX icon

Marshall Wace North America’s Crinetics Pharmaceuticals CRNX Stock Holding History

Marshall Wace North America’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-43,671
Closed -$824K – 1473
2021
Q2 		$824K Buy
+43,671
New +$767K ﹤0.01% 1068
2019
Q4 		– Sell
-2,965
Closed -$45K – 1332
2019
Q3 		$45K Sell
2,965
-70,960
-96% -$1.38M ﹤0.01% 1168
2019
Q2 		$1.85M Buy
73,925
+72,014
+3,768% +$1.78M 0.01% 586
2019
Q1 		$43K Buy
+1,911
New +$47K ﹤0.01% 1291
2018
Q4 		– Sell
-31,241
Closed -$895K – 1501
2018
Q3 		$895K Buy
+31,241
New +$928K 0.01% 620

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Marshall Wace North America's CRNX Position: Q3 2021 in Review

Marshall Wace North America sold out of Crinetics Pharmaceuticals (CRNX) in Q3 2021, closing a stake of 43,671 shares — an estimated $824K sold.

Marshall Wace North America first reported a position in CRNX in Q3 2018 and held it in 5 quarters. The position peaked at $1.85M in Q2 2019. 94 funds tracked by Wall St. Rank hold CRNX as of Q3 2021.

  • Marshall Wace North America reported no remaining Crinetics Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Marshall Wace North America sold 43,671 Crinetics Pharmaceuticals shares in Q3 2021, an estimated $824K.
  • Marshall Wace North America first reported a position in Crinetics Pharmaceuticals in Q3 2018 and held it in 5 quarters.
  • Marshall Wace North America's Crinetics Pharmaceuticals position peaked at $1.85M in Q2 2019.
  • 94 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.